Promoted Content Promoted Content

X

Find Approved Drugs for Cardiology/Vascular Diseases in Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Labetalol Hydrochloride

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: ProvideGx

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 21, 2021

            Details:

            The five medicines include: diazepam, labetalol, lorazepam, fentanyl citrate and 0.9% sodium chloride injection. Deal aims support to healthcare providers, helping to meet the immediate and long-term supply needs of drugs necessary to a range of patient care interventions.